MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.460
-0.010
-0.40%
Closed 18:28 09/17 EDT
OPEN
2.480
PREV CLOSE
2.470
HIGH
2.560
LOW
2.460
VOLUME
49.98K
TURNOVER
--
52 WEEK HIGH
5.39
52 WEEK LOW
2.280
MARKET CAP
35.20M
P/E (TTM)
-1.8270
1D
5D
1M
3M
1Y
5Y
Penny Stocks to Buy Using Technical Analysis for September 2021
If you've been meaning to invest in penny stocks and learn more about technical analysis, there's no better time than now.
Investopedia · 09/02 19:31
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 08/31 13:32
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unme...
GlobeNewswire · 08/30 12:30
Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates
Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 22:45
BRIEF-Acer Therapeutics Posts Q2 Loss Per Share Of $0.23
reuters.com · 08/10 21:42
Acer Therapeutics Q2 EPS $(0.23) Up From $(0.56) YoY
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.23) per share. This is a 58.93 percent increase over losses of $(0.56) per share from the same period last year.
Benzinga · 08/10 20:52
BRIEF-Acer Therapeutics And Relief Therapeutics Announce Submission Of A New Drug Application To The U.S. FDA For Acer-001 For Treatment Of Urea Cycle Disorders
reuters.com · 08/09 14:21
20 Stocks Moving in Monday's Pre-Market Session
Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss for its second quarter.
Benzinga · 08/09 11:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACER stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 1.78M
% Owned: 12.42%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
5
41.27K
New
4
55.24K
Decreased
10
26.14K
Sold Out
4
161.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer/Chief Operating Officer
Harry Palmin
Other
Jefferson Davis
Other
John Klopp
Other
Matthew Seibt
Secretary
Donald Joseph
Independent Director
Jason Amello
Independent Director
John Dunn
Independent Director
Michelle Griffin
No Data
  • All
  • Financials
  • Insiders
More
About ACER
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.